Home > Result Summaries: Compounds > GSK2190915 Result Summaries: GSK2190915 GSKStudy ID Phase Title Summary (Download) 111834 phase 2 A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma (1 citation(s)) 112025 phase 2 A multi-centre, randomized, double-blind, five-way crossover study evaluating the dose response and duration of action of GSK2190915 compared to placebo in subjects with mild asthma who experience exercise induced bronchoconstriction. (0 citation(s)) 112356 phase 2 A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthma (0 citation(s)) 114255 phase 2 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 years of age. (0 citation(s)) 114387 phase 2 A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID (0 citation(s)) 116626 n\a PGx364: An ADME pharmacogenetic investigation to evaluate the pharmacokinetic variability of GSK2190915 in subjects from Studies LPA111834, LPA112025, and LPA112356 (0 citation(s))
